On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) voted to recommend the use of SHINGRIX in older adults to help protect against shingles.¹

**ACIP-APPROVED RECOMMENDATIONS FOR SHINGRIX (ZOSTER VACCINE RECOMBINANT, ADJUVANTED)**

**ACIP voted that SHINGRIX is¹:**
- Recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged 50 years and older
- Recommended for the prevention of herpes zoster and related complications for immunocompetent adults who previously received zoster vaccine live (ZVL)
- Preferred over zoster vaccine live (ZVL) for the prevention of herpes zoster and related complications

**Please note:**
ACIP recommendations are reviewed and approved by the director of the CDC. Once approved, these recommendations will be published in the *Morbidity and Mortality Weekly Report (MMWR)*. The CDC may provide additional guidance in the final publication. At that time, the recommendations will become official policy.

For more information on the ACIP recommendation of SHINGRIX, visit: cdc.gov/shingles/vaccination.html

**Indication**
SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

**Important Safety Information**
- In clinical studies, solicited adverse reactions were pain (78.0%), redness (38.1%), and swelling (25.9%) at the injection site; myalgia (44.7%); fatigue (44.5%); headache (37.7%); shivering (26.8%); fever (20.5%); and gastrointestinal symptoms (17.3%)

Please see additional Important Safety Information and other Important Considerations for SHINGRIX on back and accompanying full Prescribing Information.
Important Considerations

- There are limited data on vaccination with SHINGRIX of patients previously vaccinated with ZVL
  - In a Phase 3 study, humoral immunogenicity was non-inferior among subjects previously vaccinated at least 5 years earlier with ZVL
  - No apparent safety differences were observed between study groups within 30 days post-dose 2 of SHINGRIX
  - Solicited local and systemic symptoms were similar between study groups
- The levels of antibodies and immune cells that correlate with protection against shingles disease have not been clearly defined
- There are no head-to-head clinical trials comparing the efficacy and safety of SHINGRIX to ZVL

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In clinical studies, solicited adverse reactions were pain (78.0%), redness (38.1%), and swelling (25.9%) at the injection site; myalgia (44.7%); fatigue (44.5%); headache (37.7%); shivering (26.8%); fever (20.5%); and gastrointestinal symptoms (17.3%)
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see accompanying full Prescribing Information.